DEUCRAVACITINIB, AN ORAL, SELECTIVE TYROSINE KINASE 2 INHIBITOR, IN A PHASE 2 TRIAL IN PSORIATIC ARTHRITIS: ACHIEVEMENT OF MINIMAL DISEASE ACTIVITY AND ITS COMPONENTS

被引：0
|
作者：
Kavanaugh, A. [1 ]
Coates, L. [2 ]
Merola, J. F. [3 ]
Mease, P. J. [4 ,5 ]
Nowak, M. [6 ]
Banerjee, S. [7 ]
Hippeli, L. [8 ]
Lehman, T. [9 ]
机构：
[1] Univ Calif San Diego, Rheumatol, La Jolla, CA 92093 USA
[2] Univ Oxford, Orthopaed Rheumatol & Musculoskeletal Sci, Oxford, England
[3] Harvard Med Sch, Brigham & Womens Hosp, Dermatol, Boston, MA 02115 USA
[4] Providence St Joseph Hlth, Swedish Med Ctr, Seattle, WA USA
[5] Univ Washington, Rheumatol Res, Seattle, WA 98195 USA
[6] Bristol Myers Squibb, Clin R&D, Princeton, NJ USA
[7] Bristol Myers Squibb, Rheumatol & Dermatol, Princeton, NJ USA
[8] Bristol Myers Squibb, Biostats, Princeton, NJ USA
[9] Bristol Myers Squibb, WW Med Immunol, Princeton, NJ USA
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2022年 / 81卷
关键词：
D O I：
10.1136/annrheumdis-2022-eular.1849
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
POS1039
引用
收藏
页码：835 / 835
页数：1
相关论文
共 50 条
  • [31] A Physiologically Based Pharmacokinetic Model of an Oral Tyrosine Kinase 2 Inhibitor Deucravacitinib in Healthy Adults
    Chen, Xinyue
    Lin, Zhoumeng
    JOURNAL OF CLINICAL PHARMACOLOGY, 2025,
  • [32] Deucravacitinib, a selective tyrosine kinase 2 inhibitor, for the treatment of moderate-to-severe plaque psoriasis
    Galluzzo, Marco
    Vellucci, Laura
    Marcelli, Lorenzo
    Paganini, Claudia
    Bianchi, Luca
    Talamonti, Marina
    EXPERT OPINION ON PHARMACOTHERAPY, 2023, 24 (09) : 981 - 988
  • [33] Deucravacitinib, an Oral, Allosteric, Tyrosine Kinase 2 (Tyk2) Inhibitor, in Patients With Active Systemic Lupus Erythematosus: Patient-Reported Outcomes in a Phase 2 Trial
    Mosca, Marta
    Arnaud, Laurent
    Askanase, Anca
    Hobar, Coburn
    Becker, Brandon
    Singhal, Shalabh
    Banerjee, Subhashis
    Pomponi, Samantha
    Choi, Jiyoon
    Coles, Adrian
    Touma, Zahi
    Keeling, Stephanie
    Strand, Vibeke
    JOURNAL OF RHEUMATOLOGY, 2024, 51 : 31 - 32
  • [34] Deucravacitinib, an Oral, Allosteric, Tyrosine Kinase 2 (TYK2) Inhibitor, in Patients with Active Systemic Lupus Erythematosus: Patient-Reported Outcomes in a Phase 2 Trial
    Mosca, Marta
    Arnaud, Laurent
    Askanase, Anca
    Hobar, Coburn
    Becker, Brandon
    Singhal, Shalabh
    Banerjee, Subhashis
    Pomponi, Samantha
    Choi, Jiyoon
    Coles, Adrian
    Strand, Vibeke
    ARTHRITIS & RHEUMATOLOGY, 2023, 75 : 4611 - 4614
  • [35] Biomarker Changes with Selective Tyrosine Kinase 2 Inhibitor, Deucravacitinib, in PsA: Effects on Disease Markers and Tyrosine Kinase 2-versus Janus Kinase 1/2/3-mediated Pathways
    FitzGerald, Oliver
    Gladman, Dafna
    Mease, Philip
    Ritchlin, Christopher
    Smolen, Josef
    Gao, Lu
    Hu, Sarah
    Nowak, Miroslawa
    Banerjee, Subhashis
    Catlett, Ian
    Guo, Xiang
    ARTHRITIS & RHEUMATOLOGY, 2021, 73 : 1013 - 1015
  • [36] Effect of Deucravacitinib on the Psoriatic Arthritis Impact of Disease Questionnaires 12 and 9: Analysis of a Phase 2 Study of Active Psoriatic Arthritis
    Gossec, Laure
    Coates, Laura
    Ogdie--Beatty, Alexis
    Mease, Philip
    Lehman, Tom
    Nowak, Miroslawa
    Wei, Lan
    Ye, June
    Choi, Jiyoon
    Zhuo, Joe
    Becker, Brandon
    ARTHRITIS & RHEUMATOLOGY, 2021, 73 : 1520 - 1522
  • [37] Phase 2 Trial of Selective Tyrosine Kinase 2 Inhibition in Psoriasis
    Papp, Kim
    Gordon, Kenneth
    Thaci, Diamant
    Morita, Akimichi
    Gooderham, Melinda
    Foley, Peter
    Girgis, Ihab G.
    Kundu, Sudeep
    Banerjee, Subhashis
    NEW ENGLAND JOURNAL OF MEDICINE, 2018, 379 (14): : 1313 - 1321
  • [38] EFFECT OF DEUCRAVACITINIB ON THE PSORIATIC ARTHRITIS IMPACT OF DISEASE (PsAID) QUESTIONNAIRES 12 AND 9: ANALYSIS OF A PHASE 2 STUDY OF ACTIVE PSORIATIC ARTHRITIS
    Gossec, L.
    Coates, L. C.
    Ogdie, A.
    Mease, P. J.
    Lehman, T.
    Nowak, M.
    Wei, L.
    Ye, J.
    Choi, J.
    Zhuo, J.
    Becker, B.
    ANNALS OF THE RHEUMATIC DISEASES, 2021, 80 : 1316 - 1317
  • [39] Deucravacitinib, an Oral, Allosteric, Selective Tyrosine Kinase 2 Inhibitor, in Patients with Plaque Psoriasis Who Screened Positive for Psoriatic Arthritis in POETYK PSO-1 and POETYK PSO-2: Effect on Joint Pain and Peripheral Joint Disease vs Placebo and Apremilast
    Merola, Joseph
    Mease, Philip J.
    Armstrong, April W.
    Strand, Vibeke
    Lehman, Thomas
    Choi, Jiyoon
    Becker, Brandon
    Zhong, Yichen
    Colombo, Matthew J.
    Thaci, Diamant
    Bili, Androniki
    Gottlieb, Alice B.
    ARTHRITIS & RHEUMATOLOGY, 2023, 75 : 4462 - 4465
  • [40] Deucravacitinib, an Oral, Selective, Allosteric Tyrosine Kinase 2 Inhibitor, in Patients with Moderate to Severe Psoriasis: Long-Term Efficacy in Placebo Crossovers
    Warren, Richard B.
    Lebwohl, Mark
    Imafuku, Shinichi
    Bagel, Jerry
    Armstrong, April W.
    Passeron, Thierry
    Linaberry, Misti
    Hoyt, Kim
    Napoli, Andrew
    Kisa, Renata M.
    Thaci, Diamant
    Blauvelt, Andrew
    ARTHRITIS & RHEUMATOLOGY, 2023, 75 : 4346 - 4348
12345